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Objectives: Recent clinical data have suggested high raltegravir concentrations in gut tissue after oral adminis-
tration, with implications for treatment and prevention. We have used in silico, in vitro, ex vivo and in vivomodels
to further investigate the accumulation of raltegravir in gut tissue.
Methods: Affinity of raltegravir for gut tissue was assessed in silico (Poulin–Theil method), in vitro (Caco-2
accumulation) and ex vivo (rat intestine) and compared with the lipophilic drug lopinavir. Finally, raltegravir
concentrations in plasma, gut contents, small intestine and large intestine were determined after oral dosing
to Wistar rats 1 and 4 h post-dose. Samples were analysed using LC-MS/MS and scintillation counting.
Results: Gut tissue accumulation of raltegravir was less than for lopinavir in silico, in vitro and ex vivo (P,0.05).
After oral administration to rats, raltegravir concentrations 4 h post-dose were lower in plasma (0.05 mM)
compared with small intestine (0.47 mM, P¼0.06) and large intestine (1.36 mM, P,0.05). However, raltegravir
concentrations in the contents of both small intestine (4.0 mM) and large intestine (40.6 mM) were also high.
Conclusions: In silico, in vitro and ex vivo data suggest low raltegravir accumulation in intestinal tissue. In contrast,
in vivo animal data suggest raltegravir concentrates in intestinal tissue even when plasma concentrations are
minimal. HoweverQ1 , high raltegravir concentrations in gut contents are the likely driving factor, rather than blood-
to-tissue. The methods described can be combined with clinical investigations to provide a complete strategy for
selection of drugs with high gut accumulation.
Keywords: PreP, HIV, tissue drug concentrations
Introduction
ART has been extremely effective in improving mortality andmor-
bidity in HIV infection. However, despite successful treatment,
patients still experience re-emergence of virus following cessation
of ART.1 Current ART is not capable of eradicating HIV from
infected individuals, which is due to the existence of latently
infected cells and the continuing replication of HIV in sanctuary
sites, where drug concentrations are insufficient to halt viral rep-
lication.2 – 4 Antiretrovirals are also being investigated for pre-
exposure prophylaxis (PreP), where drugs are administered to
individuals at high risk of infection.5
The gut-associated lymphoid tissue (GALT) is important in the
context of PreP and eradication. The GALT harbours 80% of total
lymphocytes in humans, which are the primary cell type infected
by HIV, and consists of mesenteric lymph nodes, Peyer’s patches
in the small intestine and follicular aggregates in the large intes-
tine and caecum.6 From an eradication perspective, the GALT can
produce new virus in patients with undetectable viral loads in per-
ipheral blood and this virus is capable of subsequent migration to
other sites.7,8 The GALT shows incomplete immunological recov-
ery following initiation of ART, which could be associated with
inadequate drug exposure.9,10 From a PreP perspective, the GALT
is a central site for establishment of primary HIV infection, where
up to 60%of lymphocytes in the lamina propria are lost as early as
2 weeks after infection.9 Therefore, sufficient and sustained con-
centrations of antiretrovirals are required in the GALT to fully block
continuing viral replication at this site (eradication) and to prevent
the initial establishment of GALT-associated infection following
exposure (PreP).
Clinical trials have previously attempted to quantify antiretroviral
concentrations in human intestinal tissue, where tissue is sampled,
processed and analysed for drug content. When administered as a
single oral dose to HIV-negative men, the relative exposures of dar-
unavir, ritonavir and etravirine in rectal tissue compared with blood
plasma were 1.26, 5.77 and 15.7, respectively.11 A similar study
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gave the relative exposure of maraviroc in rectal tissue compared
with blood plasma as 7.48 following single dosing, increasing to
26.2 following multiple dosing.12 When administered to a healthy
cohort of men and women, relative exposures of tenofovir and
emtricitabine in rectal tissue compared with blood plasma were
32.8 and 3.2, respectively.13 Interestingly, the active forms of
these drugs, tenofovir diphosphate and emtricitabine triphosphate,
showed extremely high exposures in rectal tissue even compared
with parent drug.
The integrase inhibitor raltegravir has shown by far the highest
relative exposure in gut tissue of all antiretrovirals tested.14
Following a single 400 mg standard raltegravir dose given to
HIV-negative men, a relative exposure compared with blood
plasma of 39, 68 and 160 was reported in rectal tissue, splenic
flexure and terminal ileum, respectively. Exposure was even
higher following 7 days of twice-daily dosing, with a relative
exposure of 231, 659 and 156 in rectal tissue, splenic flexure
and terminal ileum, respectively. In contrast, dolutegravir,
another integrase inhibitor, showed lower concentrations in rectal
tissue compared with blood plasma, with a relative exposure of
0.17 following 8 days of once-daily dosing.15
Knowledge of drug concentrations in the GALT is crucial to
understand the factors dictating exposure and for appropriate
selection of drugs for PreP. Intestinal tissue sampling may help
in clarification but there are complications when attempting to
distinguish between intracellular and extracellular drug measure-
ments. Specifically, there is a possibility of artefacts arising
through contamination of tissue with unabsorbed drug in the
intestinal contents. Also, drug concentrations in whole intestinal
tissue may not necessarily represent exposure of drug in the
GALT: it is acknowledged that there is currently a paucity of infor-
mation regarding the relationship between drug concentrations in
the GALT and the use of whole tissue as a surrogate. The purpose
of this study was to use several separate methodological
approaches (in silico, in vitro, ex vivo and in vivo) to investigate
the affinity of raltegravir for intestinal cells and tissue and to fur-
ther understand the apparent high tissue-associated raltegravir
exposure observed in patients.
Materials and methods
Materials
Caco-2 cells were purchased from the European Collection of Cell Cultures
(Salisbury, UK). Raltegravir potassium salt was purchased from
Selleckchem (Munich, Germany) and [3H]raltegravir was a gift from
Merck (NJ, USA). Lopinavir was a gift from Abbott (IL, USA). [3H]lopinavir
was purchased from Moravek Biochemicals (CA, USA). Ultima Gold scintil-
lation fluid and OptiSolvTM tissue solubilizer were purchased from Perkin
Elmer (Boston, MA, USA). Male Wistar rats (ordered at 100–125 g, 33–
35 days old) were purchased from Charles River (Kent, UK). All other
drugs and reagents were obtained from Sigma (Poole, UK).
In silico prediction of intestinal tissue affinity
Intestine-to-plasma affinity ratios were predicted in silico for raltegravir
and lopinavir using the Poulin–Theil method.16 Values for drug lipophilicity
(log P), free fraction of drug in plasma (fu) and pKa were combined with
data on plasma and intestinal tissue constituents (fraction of neutral
lipids, phospholipids, extracellular space and water) to estimate the affin-
ity of the drug for intestinal tissue over plasma. The log P and pKa of ralte-
gravir were previously determined by our group.17 The fu of raltegravir was
obtained from the literature.18 The log P of lopinavir was predicted using
the ALOGP method.19 The fu and pKa of lopinavir were obtained from the
literature.20
In vitro accumulation using Caco-2 cells
Caco-2 cells weremaintained in cell culture (378C, 5%CO2) by passaging at
70% confluence using cell culture medium [DMEM/15% (v/v) FCS]. The
passage number of the cells used in this study was between 30 and 35.
For the experiment, Caco-2 cells were seeded (5×104 cells/mL) into
6-well plates and cultured for 5 days to allow plate surface coverage
[DMEM/15% (v/v) FCS, 378C, 5% CO2]. Medium was removed and cells
werewashedwith warmHanks balanced salt solution (HBSS) and replaced
with the appropriate pH-buffered incubation solution and allowed to
equilibrate (378C, 5% CO2, 15 min). A range of pH conditions were used
to simulate the varied pH found in the gastrointestinal system.
Incubation solutions were adjusted using hydrochloric acid and sodium
hydroxide and consisted of HBSS containing 10 mM MOPS (used for pH 5
and pH 6) or HBSS containing 25 mM HEPES (used for pH 7 and pH 8).
Raltegravir (1 mM) was included in the wells and plates were incubated
(2 mL, 378C, 5% CO2, 10 min, n¼3 replicates). Parallel experiments
were also performed to assess the accumulation of lopinavir (2 mL,
0.4 mCi/mL, 1 mM, 378C, 5% CO2, 10 min, n¼3 replicates) as a comparator.
Following incubation of either raltegravir or lopinavir, 100 mL extracellular
samples were taken for analysis, wells were washed three times with ice-
cold HBSS and 500 mL of tap water was added to each empty well to lyse
cells. Plates were kept at2208C overnight to facilitate the removal of cells.
Plates were thawed and lopinavir samples were analysed by liquid scintil-
lation counting (Beckman TRI-CARBw). For raltegravir samples, 500 mL of
acetonitrile was added to each well to release drug from protein. The
well contents were transferred to separate 1.5 mL tubes for centrifugation
(10 min, 3000 g, 228C) and supernatant was collected. Supernatant was
then vacuum dried and reconstituted in 150 mL of HPLC-grade water for
analysis using a previously validated LC-MS/MS method.17
Accumulation experiments using ex vivo rat
intestinal tissue
Four Q2male Wistar rats were sacrificed using Schedule 1 procedures, blood
sampleswere taken by cardiac puncture and stored in heparin tubes on ice
for future analysis. Intestinal tissue was then harvested. Specifically, the
section of tissue immediately following the duodenum (the jejunum)
was used for the ‘small intestine’ and the section of tissue immediately
following the caecum (the colon) was used for the ‘large intestine’.
Tissue was cut open and rinsed with ice-cold PBS solution to remove intes-
tinal contents. Approximately 100 mg of small intestine tissue was incu-
bated with human plasma (3 mL of plasma, 378C, 4 h, 60 rpm shaker,
n¼4) containing either raltegravir or lopinavir (both at 1 mCi/mL, 50 mM).
A parallel incubation was also performed using 100 mg of large intes-
tine. Following incubation, a 100 mL extracellular sample was taken from
wells for determination of extracellular drug concentrations. Tissue was
removed and washed thoroughly using ice-cold PBS. Tissue solubilization
was performed using the following protocol. Each tissue segment was
added to OptiSolvTM tissue solubilizer to the equivalent of 1 mL for every
100 mg of tissue. Mixtures were kept in a 508C water bath for 18 h and
allowed to cool to room temperature in a fume cupboard. Hydrogen per-
oxidewas added to eachmixture (600 mL per 100 mg of tissue) and left for
1 h on ice to decolorize the contents. Glacial acetic acid was then added to
neutralize the mixtures (1 part neutralizer for every 11 parts solubilizer
used). The extracellular samples and the dissolved tissue samples were
added to 10 mL of scintillation fluid and analysed by liquid scintillation
counting (Beckman TRI-CARBw). When calculating concentrations of
drug in tissue, the previously published conversion factor was used
where 1.04 g of intestinal tissue is equivalent to 1 mL.14
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Determination of raltegravir concentrations in vivo
in plasma and intestinal tissue after oral
administration to rats
All in vivo experiments were undertaken following institutional and national
standards for animal care and experimentation. The protocol was approved
for use by the Research Ethics Committee at the University of Liverpool.
Raltegravir concentrations in blood plasma, small intestine tissue, large
intestine tissue, small intestine contents and large intestine contents were
determined in vivo following oral dosing directly into the stomach using an
oral gavage (8 mg/kg, 5 mL/kg, dosed using PBS, n¼3) tomaleWistar rats
with 1 h post-dose sampling of blood and tissue. A parallel experiment
was also performed where sampling of plasma and tissue was taken 4 h
post-dose. At the point of sampling, rats were sacrificed using Schedule 1
procedures and blood samples were taken by cardiac puncture and stored
in heparin tubes on ice for future analysis. Intestinal tissue was harvested
as described above. Tissues were cut open and the contents removed and
stored on ice for analysis. Tissuewas then rinsed with ice-cold PBS solution
to remove the remaining intestinal contents and was stored on ice. Blood
samples were centrifuged (10 min, 3000 g, 228C) and supernatant plasma
was removed. Plasmawas added to solvent (100 mLof plasma into 300 mL
of methanol containing 100 nM ritonavir as internal standard), vortexed
for 5 min and centrifuged (10 min, 3000 g, 228C). Intestinal content was
added to solvent (100 mL of intestinal content into 300 mL of methanol
containing 100 nM ritonavir as internal standard), vortexed for 5 min
and centrifuged (10 min, 3000 g, 228C). Intestinal tissue was mechanic-
ally homogenized on ice until having a liquid consistency, added to solvent
(100 mL of homogenate into 300 mL of methanol containing 100 nM
ritonavir as internal standard), vortexed for 5 min and centrifuged
(10 min, 3000 g, 228C). The supernatants from the plasma, intestinal con-
tent and intestinal tissue samples were all carefully removed and 200 mL
of each supernatant was vacuum dried and reconstituted in 100 mL of
HPLC-grade water for analysis using a previously validated LC-MS/MS
method.17 To account for the existence of amatrix effect, calibration curves
were created using the different matrices (plasma, intestinal tissue and
intestinal contents). Quality control (QC) samples (high QC 2000 ng/mL,
medium QC 200 ng/mL and low QC 100 ng/mL) were included in analyses
for confirmation, where a .20% deviation from the standard curve was
considered a failed analysis. When calculating concentrations of raltegravir
in tissue, the previously published conversion factor was used where 1.04 g
of intestinal tissue is equivalent to 1 mL.14
Statistical analysis
Datawere analysed using SPSS 20 forWindows. All datawere tested for nor-
mality using the Shapiro–Wilk test. An independent t-test was used to
determine significance of normally distributed data. The Mann–Whitney
U-test was used for all other data. A two-tailed P value of ,0.05 was
accepted as being statistically significant. A two-tailed P value of ≤0.1
was accepted as showing a trend.
Results
In silico prediction of intestinal tissue affinity
The log P, fu and pKa of raltegravir was 0.4, 0.17 and 6.7 (acid),
respectively. The log P and fu of lopinavir was 3.9 and 0.02,
respectively. The pKa of lopinavir was not within the range of
physiological pH. The intestine-to-plasma affinity ratios of ralte-
gravir and lopinavir were predicted as 0.53 and 6.38, respectively.
In vitro accumulation using Caco-2 cells
When Caco-2 cells were incubatedwith 1 mM raltegravir for 10 min,
intracellular raltegravir concentrations were 1.41+0.33 mM (pH 5),
0.94+0.21 mM (pH 6), 0.72+0.05 mM (pH 7) and 0.42+0.02 mM
(pH 8) (Figure 1a). Intracellular raltegravir concentrations were
not significantly different from incubation concentrations when
pH 5 (P¼0.09) and pH 6 (P¼0.68) buffers were used, but were sig-
nificantly lower than incubation concentrations when pH 7
(P¼0.01) and pH 8 (P,0.01) buffers were used. Extracellular con-
centrations of raltegravir following the 10 min incubations using pH
5, pH 6, pH 7 and pH 8 buffers were 0.95+0.10, 1.02+0.08,
1.05+0.11 and 0.97+0.15 mM, respectively. When Caco-2 cells
were incubated with 1 mM lopinavir for 10 min, intracellular lopina-
vir concentrations were 24.8+2.8 mM (pH 5), 25.4+2.0 mM (pH 6),
25.8+1.2 mM (pH 7) and 27.5+2.5 mM (pH 8) (Figure 1b).
Intracellular lopinavir concentrations were significantly higher
than incubation concentrations for all pH buffers used (P,0.01)
and did not differ across the pH range (P.0.05 for all comparisons).
Extracellular concentrations of lopinavir following the 10 min incu-
bations using pH 5, pH 6, pH 7 and pH 8 buffers were 0.83+0.07,
0.80+0.08, 0.80+0.14 and 0.78+0.03 mM, respectively.
Accumulation experiments using ex vivo rat
intestinal tissue
In ex vivo studies when incubating 50 mM drug with Wistar rat
intestinal tissue, raltegravir accumulated less than lopinavir in
both the small intestine tissue (29.6+2.0 versus 65.7+6.8 mM,
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Figure 1. (a) Accumulation of raltegravir in Caco-2 cells (mM+SD, 1 mM initial drug incubation, 15×106 cells, 378C, 10 min, n¼3) using transport buffer at
pH 5, 6, 7 or 8. (b) Accumulation of lopinavir in Caco-2 cells (mM+SD, 1 mM initial drug incubation, 15×106 cells, 378C, 10 min, n¼3) using transport buffer
at pH 5, 6, 7 or 8. RAL, raltegravir; LPV, lopinavir.
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P,0.05; Figure 2a) and the large intestine tissue (34.9+3.3 versus
53.5+1.9 mM, P,0.05; Figure 2b). Tissue-associated raltegravir
concentrations did not match the levels added to the plasma
(P,0.01). Lopinavir showed significantly higher concentrations in
the small intestine tissue compared with the plasma (P¼0.03),
whereas only a trend was observed for higher concentrations in
the large intestine tissue compared with the plasma (P¼0.051).
Concentrations of raltegravir in plasma at the 4 h timepoint
in the small intestine and large intestine incubations were
46.1+1.5 and 50.5+1.0 mM, respectively. Concentrations of lopi-
navir in plasma at the 4 h timepoint in the small intestine and
large intestine incubations were 47.5+2.5 and 47.0+3.0 mM,
respectively.
Determination of raltegravir concentrations in vivo
in plasma and intestinal tissue after oral
administration to rats
After oral administration to Wistar rats, raltegravir concentrations
decreased between the 1 and 4 h sampling periods in plasma
(0.63+0.13 to 0.05+0.03 mM, P,0.01) and in the small intestine
(1.4+0.26 to 0.47+0.27 mM, P¼0.01), but did not change in the
small intestine contents (5.2+3.8 to 4.0+3.2 mM, P¼0.72).
Conversely, increases in the large intestine (0.38+0.15 to
1.36+0.50 mM, P,0.03) and large intestine contents (0.15+0.09
to 40.6+3.3 mM, P,0.01) were observed between the 1 and 4 h
sampling periods (Figure 3). If each timepoint is evaluated separ-
ately, it can be observed that at 1 h the drug concentrations in
plasma showed a trend to being lower than in the small intestine
(P¼0.09) and small intestine contents (P¼0.1). TheQ3 drug concentra-
tions in plasma showed a trend to being higher than in the large
intestine (P¼0.09) and was significantly higher than in the large
intestine contents (P,0.01). It can be observed that at 4 h, the
drug concentrations in plasma showed a trend to being lower
than in the small intestine (P¼0.06) and small intestine contents
(P¼0.1) and was significantly lower than in the large intestine
(P¼0.01) and large intestine contents (P,0.01).
Discussion
The in silico, in vitro and ex vivo data presented here all suggest
that raltegravir has less propensity than lopinavir to accumulate
in intestinal cell lines and intestinal tissue. In contrast, in vivo ani-
mal data suggest raltegravir concentrations in the intestinal tissue
can remain high even when raltegravir plasma concentrations are
reduced. At the 4 h sampling point, the concentration of raltegra-
vir is 26-fold higher in the large intestine tissue than in blood
plasma. However, at the 4 h sampling point, the concentration
of raltegravir in the large intestine contents is much higher still,
showing a 29-fold higher concentration than in the tissue itself.
Therefore Q4, it seems likely that the high raltegravir concentrations
detected in tissue are driven primarily by the local distribution of drug
from the adjacent intestinal contents, rather than blood-to-tissue.
Previously Q5published raltegravir pharmacokinetic profiles in rats
show the Cmax to be 1 h post-dose and a large decrease in con-
centrations at after 4 h, which support our data.21 The mean gas-
tric emptying time in Wistar rats is 1.7 h, so the 1 h timepoint
represents when raltegravir has begun to empty from the
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stomach and be absorbed by the small intestine, with very little
yet reaching the large intestine.22 The mean transit time to the
large intestine in Wistar rats is 3.4 h, so the 4 h timepoint repre-
sents when unabsorbed raltegravir has mostly entered the large
intestine, explaining the large increase in the large intestine con-
tents seen between the 1 and 4 h timepoints. Despite thoroughly
washing the contents from tissue following sampling, it is possible
that not all raltegravir was removed from the surface of the tis-
sues. For context, at the 4 h timepoint, if only 5 mL of the large
intestine contents remained for every 100 mg of tissue, then
this would equate to a 2 mM contamination for the tissue data.
It is also important to note that ex vivo experiments measured
total radioactivity (raltegravir parent, metabolites etc.) whereas
the in vivo experiments measured just raltegravir in the parent
form. As the in vivo samples were analysed using MS, it can be
assumed that all detected drug is in the active form. The amount
of raltegravir bound to gut contents was not determined, but it
can be predicted that it would not be particularly high as raltegra-
vir is not particularly lipophilic (log P of 0.59 at pH 7), is a weak acid
with a pKa of 6.7 and does not have a restrictively high plasma
protein binding (83% bound).
Humans and rats can differ in characteristics known to affect
drug metabolism, distribution and elimination and it is important
to consider this when interpreting results in this study. TheQ6 free
fraction of raltegravir is 17% in human plasma and is similarly
mild at 26% in rat plasma. Therefore, this factor is unlikely to sub-
stantially alter raltegravir pharmacokinetics between the species.
RaltegravirQ7 is metabolized to an inactive form by UGT1A1 in
humans and the rat ugt1a1 enzyme is believed to play a similar
role (although this has not been empirically shown).21,23 Rats, as
well as mice, dogs and even non-human primates, are generally
poor predictors of drug bioavailability in humans, making it poten-
tially difficult to utilize these animals for optimizing drug exposure
in intestinal tissue and the GALT.24
Raltegravir shows very high interpatient and intrapatient phar-
macokinetic variability and absorption is influenced by pH-altering
agents, metal-containing agents and food.17,25–28 When admi-
nistered as a 400 mg oral tablet, the absorption of raltegravir is
believed to be incomplete, although total bioavailability has not
been determined in humans. Our group previously published a
physiologically based pharmacokinetic model investigating the
influence of gastrointestinal pH and metal-containing products
on raltegravir exposure, where the fraction of drug absorbed
was predicted to be incomplete in most simulated subjects,
with some subjects showing as low as 13% absorption.29
Considering that simulated subjects were given a single 400 mg
of raltegravir tablet, this would potentially leave up to 354 mg of
raltegravir unabsorbed in the intestinal contents. In the context
of PreP, it is unknown whether this ‘reservoir’ of unabsorbed drug
in the intestinal contents may provide any local protection of the
rectal tissue from infection, in a similar way as in as the use of vagi-
nal and rectal microbicides.30,31 It is also unknown whether drug
concentrations are maintained in rectal tissue following enemas
or defecation.
If both the percentage bioavailability of an antiretroviral and
the dose size are taken into account, an estimate can be made
of the amount of parent drug that was not bioavailable.32 – 36
Using published clinical data, a plot comparing this value with
the relative exposure of each drug in rectal tissue is shown
(Figure 4).11,13,15 The relative exposures of drugs in rectal tissue
were taken from single-dose studies. Using bivariate analysis, a
correlation is observed where a high amount of drug that is not
bioavailable is associated with a high relative drug concentration
in rectal tissue (P¼0.042, R2¼0.88). The bioavailability of dolute-
gravir is unknown, but the study that detected low dolutegravir
concentrations in rectal tissue also found,15% drug in the rectal
mucosal fluid compared with rectal tissue, suggesting that there
would beminimal contamination issues.15 Knowing this, and con-
sidering the small dose size of dolutegravir (50 mg), the drug has
been included in the plot using an estimated 85% bioavailability.
Maraviroc was not included in the plot as its low bioavailability
(25%) is known to be metabolism-related and is not due to
poor absorption, evidenced by the low amount of radiolabelled
parent drug collected in faeces following oral administration
(25% of total administered drug).37 Both darunavir andmaraviroc
undergo high CYP3A4-mediated first-pass metabolism and this
may explain why the bioavailability of these drugs is not a good
indicator of rectal tissue exposure. For these highly metabolized
drugs, it can be hypothesized that a factor that could give a better
correlation to rectal tissue exposure would be the fraction of drug
absorbed, which is the fraction leaving the luminal fluid and enter-
ing the epithelial cells of the intestine.
The concentration of raltegravir in tissues required to prevent
initial infection in vivo is not known. This value is likely to differ
depending on multiple factors, such as the site of infection and
the initial amount of HIV introduced. Therefore, it is difficult to
decide on a potential target concentration for raltegravir and
other antiretrovirals for use in PreP. However, the IC95 of raltegravir
in 50% human serum ex vivo is 15 ng/mL and this is often used as
a surrogate concentration target for PreP studies in the absence of
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Figure 4. Plot comparing the amount of drug not bioavailable with the
relative exposure of each drug in rectal tissue. The relative exposures of
drugs in rectal tissue were taken from single-dose studies. Using
bivariate analysis, a correlation is observed where a high amount of
drug that is not bioavailable is associated with a high relative drug
concentration in rectal tissue (P¼0.042, R2¼0.88 Q8).
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clinical data. Furthermore, studies in a humanized mouse model
have investigated the use of raltegravir to prevent initial infection
via the rectal route and this study could be combined with a study
linking raltegravir concentrations in the intestinewith PreP success
in rodents.38
Despite the apparent association seen in Figure 4, it should be
acknowledged that drug association with rectal tissue is likely to
occur via multiple factors. Tenofovir has been shown to be an
effective drug for PreP, probably due to the mechanism of drug
action where the active form of the drug is phosphorylated and
trapped inside tissues, including the intestine.39 It should also
be acknowledged that the investigations in this study have not dir-
ectly measured raltegravir concentrations in the GALT and have
instead used complete intestinal tissue concentrations as a surro-
gate. This has also been the approach in previous antiretroviral
intestinal tissue concentration investigations undertaken in
humans. There is not a complete understanding of the relation-
ship between concentrations of antiretrovirals in the GALT and
whole intestinal tissue and this is an area that requires further
investigation if drug concentrations in whole intestine are to be
used to determine sufficient drug exposure in the GALT.
Considering the importance of the GALT for both virus eradica-
tion and for PreP, there is a current need for a rational, methodo-
logical approach for the selection and design of antiretrovirals
able to protect the GALT from infection. The methods described
here could be combined with clinical investigations to provide a
complete strategy for this selection. These data underscore the
importance of washing tissue from clinical studies to limit the
contamination with intestinal contents, especially for poorly
absorbed drugs such as raltegravir.
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